Marilyn Albert PhD

Professor of Neurology




1. Soldan A, Pettigrew C, Fagan A, Schindler S, Moghekar A, Fowler C, Li Q-X, Collins S, Carlsson C, Asthana S, Masters C, Johnson S, Morris J, Albert M, Gross A. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology, 2019; 92: e1567-e1579.

2. Bell WR, An Y, Kageyama Y, Rudow GL, Pletnikova O, Thambisetty M, O’Brien R, Moghekar AR, Albert M, Rabins PV, Resnick SM, Troncoso JC. Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer disease. Alzheimer’s and Dementia, 2019; 15: 8-16.

3. Albert M, Zhu Y, Moghekar A, Mori S, Miller M, Soldan A, Pettigrew C, Selnes O, Li S, Wang M-C. Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years. Brain, 2018; 141: 877-887. PMCID: PMC5837651.

4. Sathe G, Na C, Renuse S, Madugundu A, Albert M, Moghekar A, Pandey A. Phosphotyrosine profiling of human cerebrospinal fluid. Clinical Proteomics, 2018;15: 29. PMCID: PMC6136184.

5. Varma V, Varma S, An Y, Hohman T, Seddighi S, Casanova R, Beri A, Dammer E, Seyfried N, Pletnikova O, Moghekar A, Wilson M, Lah J, O’Brien R, Levey A, Troncoso J, Albert M, Thambisetty M. Alpha-2 macroglobulin in Alzheimer’s disease: a marker of neuronal injury through the RCAN1 pathway. Mol Psychiatry, 2017; 22: 13-23. PMCID: PMC5726508

6. Mori S, Kageyama Y, Hou Z, Aggarwal M, Patel J, Brown T, Miller M, Wu D, Troncoso J. Elucidation of white matter tracts of the human amygdala by detailed comparison between high-resolution postmortem magnetic resonance imaging and histology. Front Neuroanat. 2017; 11: 16. PMCID: PMC5348491.

7. Soldan A, Pettigrew C, Cai Q, Wang M-C, Moghekar A, O’Brien R, Albert M. Hypothetical preclinical AD groups and longitudinal cognitive change. JAMA Neurol, 2016; 73: 698-705. PMCID: PMC5173327.

8. Miller MI, Ratnanather J, Tward D, Brown T, Lee D, Ketcha M, Mori K, Wang M-C, Mori S, Albert M, Younes L. Network degeneration in Alzheimer’s disease via MRI based shape diffeomorphometry and high-field atlasing. Frontiers in Bioengineering and Biotechnology, 2015, 3:54. PMCID: PMC4515983.

9. Soldan A, Pettigrew C, Lu Y, Wang M-C, Selnes O, Albert M, Brown T, Ratnanather JT, Younes L, Miller M. Relationship of medial temporal lobe atrophy, ApoE genotype and cognitive reserve in preclinical Alzheimer’s disease. Human Brain Mapping, 2015, 36: 2826-2841. PMCID: PMC4478167.

10. Bakker A, Albert M, Krauss G, Speck C, Gallagher M. Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. Neuroimage Clin 2015; 7: 688-698.

11. Albert M, Soldan A, Gottesman R, McKhann G, Sacktor N, Farrington L, Grega M, Turner R, Lu Y, Li S, Wang MC, Selnes O. Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype. Current Alzheimers Research, 2014, 11: 773-784.

12. Younes L, Albert M, Miller MI. Inferring changepoint times of medial temporal lobe morphometric change in preclinical Alzheimer’s disease. NeuroImage, 2014; 5: 178-187. PMCID: PMC4110355.

13. Moghekar A, Li S, Lu Y, Li M, Wang M-C, Albert M, O’Brien R. Cerebrospinal fluid biomarker changes precede symptom onset of mild cognitive impairment, Neurology, 2013; 81: 1753-1758. PMCID: PMC3821715.

14. Pettigrew C, Soldan A, Li S, Lu Y, Wang MC, Selnes OA, Moghekar A, O'Brien R, Albert M. Relationship of cognitive reserve and APOE status to the emergence of clinical symptoms in preclinical Alzheimer's disease. Cogn Neurosci. 2013; 4: 136-142.